Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors
Executive Summary
If Bristol-Myers Squibb wins its bid for the remaining 83 percent of stock in Erbitux partner ImClone that it does not already own, the evolving biopharma - which itself has been the subject of takeover rumors - could become a more attractive target for potential suitors
You may also be interested in...
Mystery Suitor Thwarts Bristol’s ImClone Takeover, Or So Icahn Says
Intrigue surrounding Bristol-Myers Squibb's takeover attempt of its Erbitux (cetuximab) marketing partner ImClone reached new heights with the announcement Sept. 10 that a third-party mystery suitor has stepped in with a white knight bid
Mystery Suitor Thwarts Bristol’s ImClone Takeover, Or So Icahn Says
Intrigue surrounding Bristol-Myers Squibb's takeover attempt of its Erbitux (cetuximab) marketing partner ImClone reached new heights with the announcement Sept. 10 that a third-party mystery suitor has stepped in with a white knight bid
Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer
Pity Carl Icahn. The biotech industry's best-known activist shareholder and chairman of ImClone saw the value of his holdings plummet following the Food and Drug Administration's 2001 rejection of the company's lead cancer drug, the EGFR inhibitor Erbitux (cetuximab), and the succeeding insider-trading scandal that sent CEO Sam Waksal to jail